pain

dart board miss failure

Biotech

Vertex drops asset in acute pain after phase 2 fail

All three dose levels of Nav1.8 inhibitor VX-993 failed to improve pain intensity over a 48-hour period compared to placebo.

Darren Incorvaia Aug 4, 2025 5:34pm

AstraZeneca culls neuroscience meds in Q1 clear-out

Apr 29, 2025 7:08am

X ray illustration of a running person with pain in knee joint with blue background

Novartis culls ph. 2 knee pain trial testing anti-ADAMTS-5 asset

Apr 16, 2025 2:55pm

power lines at dusk

Novo Holdings-backed SiteOne charges up with $100M financing

Dec 18, 2024 7:00am

stop shut down close end button

Lundbeck slashes value of $250M Abide buyout after pain setback

Oct 24, 2024 7:20am

Graphic of two hands shaking under a red and purple light

Polyrizon pays $3M for license to SciSparc's CB2R agonist

Aug 19, 2024 5:27am